ArticleTransplant international : official journal of the European Society for Organ Transplantation2023
Thrombotic Microangiopathy in the Renal Allograft: Results of the TMA Banff Working Group Consensus on Pathologic Diagnostic Criteria.
Article in Transplant international : official journal of the European Society for Organ Transplantation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Establishment of a novel lupus mesenteric vasculitis mouse model and exploration of its exacerbation mechanisms.Frontiers in immunology · 2026Article
- Post-transplant Thrombotic Microangiopathy.Journal of the American Society of Nephrology : JASN · 2025Review
- Thrombotic Microangiopathy After Kidney Transplantation: Insights Into Genetic Etiology and Clinical Outcomes.Kidney international reports · 2025Article
- [Update kidney allograft pathology : A better depiction of microvascular inflammation].Pathologie (Heidelberg, Germany) · 2024Review
- Response to Letter to the Editor From Ville S. et al. About: "Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy.Kidney international reports · 2024Article
- Letter to the editor about: "Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy.Kidney international reports · 2024Article
- "Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy.Kidney international reports · 2024Article
- Thrombotic microangiopathy after kidney transplantation: Expanding etiologic and pathogenetic spectra.World journal of transplantation · 2024Review
- Paraneoplastic Syndrome After Kidney Transplantation: Frequency, Risk Factors, Differences to Paraneoplastic Occurrence of Glomerulonephritis in the Native Kidney, and Implications on Long-Term Kidney Graft Function.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Pregnancy as a susceptible state for thrombotic microangiopathies.Frontiers in medicine · 2024Review
- Delphi: A Democratic and Cost-Effective Method of Consensus Generation in Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
- Histopathology of Allograft Nephrectomies - A Ten Year Observational Study.Indian journal of nephrologyArticle
Corrections and comments
- Erratum issued
Authors and funding
27 authors at 20 institutions in 13 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Banff community summoned the TMA Banff Working Group to develop minimum diagnostic criteria (MDC) and recommendations for renal transplant TMA (Tx-TMA) diagnosis, which currently lacks standardized criteria. Using the Delphi method for consensus generation, 23 nephropathologists (panelists) with >3 years of diagnostic experience with Tx-TMA were asked to list light, immunofluorescence, and electron microscopic, clinical and laboratory criteria and differential diagnoses for Tx-TMA. Delphi was modified to include 2 validations rounds with histological evaluation of whole slide images of 37 transplant biopsies (28 TMA and 9 non-TMA). Starting with 338 criteria in R1, MDC were narrowed down to 24 in R8 generating 18 pathological, 2 clinical, 4 laboratory criteria, and 8 differential diagnoses. The panelists reached a good level of agreement (70%) on 76% of the validated cases. For the first time in Banff classification, Delphi was used to reach consensus on MDC for Tx-TMA. Phase I of the study (pathology phase) will be used as a model for Phase II (nephrology phase) for consensus regarding clinical and laboratory criteria. Eventually in Phase III (consensus of the consensus groups) and the final MDC for Tx-TMA will be reported to the transplantation community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.